培美曲塞-磷脂偶联物修饰的靶向性舒尼替尼与长春瑞滨脂质体的研制及其在体外对耐药性乳腺癌的抑制效应

doi:10.5246/jcps.2014.05.039

中国药学(英文版) ›› 2014, Vol. 23 ›› Issue (5): 287-294.DOI: 10.5246/jcps.2014.05.039

培美曲塞-磷脂偶联物修饰的靶向性舒尼替尼与长春瑞滨脂质体的研制及其在体外对耐药性乳腺癌的抑制效应

石继凤, 居瑞军, 孙梦舸, 李秀英, 赵曜, 曾凡, 吕万良^*

北京大学医学部天然药物及仿生药物国家重点实验室; 药学院药剂学系, 北京 100191

收稿日期:2014-03-03 修回日期:2014-03-31 出版日期:2014-05-23 发布日期:2014-04-06
通讯作者: Tel.: 86-10-82802683; E-mail: luwl@bjmu.edu.cn
基金资助:
Beijing Natural Science Foundation (Grant No. 7131009), the National Basic Research Program of China (Grant No. 973 program, 2013CB932501), the National Natural Science Foundation of China (Grant No. 81373343), and the Innovation Team of Ministry of Education (Grant No. BMU20110263).

Development of targeted sunitinib plus vinorelbine liposomes modified with DSPE-PEG2000-pemetrexed conjugate and the inhibitory effect toresistant breast cancer in vitro

Jifeng Shi, Ruijun Ju, Mengge Sun, Xiuying Li, Yao Zhao, Fan Zeng, Wanliang Lu^*

State Key Laboratory of Natural and Biomimetic Drugs; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2014-03-03 Revised:2014-03-31 Online:2014-05-23 Published:2014-04-06
Contact: Tel.: 86-10-82802683; E-mail: luwl@bjmu.edu.cn
Supported by:
Beijing Natural Science Foundation (Grant No. 7131009), the National Basic Research Program of China (Grant No. 973 program, 2013CB932501), the National Natural Science Foundation of China (Grant No. 81373343), and the Innovation Team of Ministry of Education (Grant No. BMU20110263).

摘要/Abstract

摘要：

乳腺癌是女性最易罹患的疾病, 而肿瘤多药耐药性通常是化疗失败的主要原因。本研究以培美曲塞(PMT)和DSPE-PEG₂₀₀₀-NH₂为原料合成了新的靶向性偶联物DSPE-PEG₂₀₀₀-PMT, 并将其修饰到脂质体表面, 制备了同时包封有舒尼替尼与长春瑞滨的靶向性脂质体, 以增强化疗药物对多药耐药性乳腺癌的治疗效果。经过质谱分析证实, 合成的靶向性载体材料DSPE-PEG₂₀₀₀-PMT与目标产物相符。建立了可同时检测舒尼替尼和长春瑞滨含量的高效液相色谱分析方法, 检测波长为215 nm, 柱温30 °C, 流动相为乙腈–0.05 M KH₂PO₄ (pH 3.5)–三乙胺(35:65:0.3, v/v/v)。舒尼替尼和长春瑞滨的最低检测浓度分别为25 ng/mL和5 ng/mL, 最低定量浓度均为0.25 µg/mL。两药在0.5–25.0 µg/mL范围内线性良好。各脂质体包封率均大于90%, 粒径均一(~90 nm), Zeta电位略显负电性。在体外耐药乳腺癌MCF-7/Adr细胞中评价了靶向性舒尼替尼与长春瑞滨脂质体的抗增殖效应。结果显示, 同对照组相比, 靶向性舒尼替尼与长春瑞滨脂质体对MCF-7/Adr细胞具有最强的抑制增殖效应。以靶向性香豆素脂质体为荧光探针, 考察了靶向性脂质体在耐药乳腺癌MCF-7/Adr细胞中的靶向性，同非靶向性制剂相比, 靶向脂质体在耐药性癌细胞中摄取最多。因此, 制备的靶向性舒尼替尼与长春瑞滨脂质体是一种新的靶向制剂, 能够被耐药乳腺癌细胞靶向性摄取, 可在体外显著抑制耐药性乳腺癌生长, 从而为耐药乳腺癌的化学治疗提供了一种新的策略。

关键词: 培美曲塞-磷脂偶联物, 舒尼替尼, 长春瑞滨, 靶向性脂质体, 耐药性乳腺癌

Abstract:

Multidrug resistance (MDR) of breast cancer is a major cause of failure in chemotherapy. In the present study,a distearoylphosphatidyl ethanolamine-polyethylene glycol-pemetrexed (DSPE-PEG₂₀₀₀-PMT) conjugate was synthesized from DSPE-PEG₂₀₀₀-NH₂ and pemetrexed, and targeted sunitinib plus vinorelbine liposomes were developed by modifying DSPE-PEG₂₀₀₀-PMT onto the surface of liposomes to overcome the MDR of breast cancer. The synthesized DSPE-PEG₂₀₀₀-PMT was confirmed to be consistent with the target product by matrix-assisted laser desorption/ionization time of flight massspectrometry (MALDI-TOF-MS). The concentrations of sunitinib and vinorelbine were measured simultaneously by highperformance liquid chromatography (HPLC). The analysis was performed on an ODS column at 30 °C at a wavelength of 215 nm with the mobile phase consisting of acetonitrile, 0.05 M KH₂PO₄ (pH 3.5) and triethylamine (35:65:0.3, v/v/v). The limits of detection for sunitinib and vinorelbine were 25 ng/mL and 5 ng/mL, respectively, and the limits of quantification for both drugs were 0.25 µg/mL. Two drugs were linearly correlated in the range of 0.5–25.0 µg/mL. For varying types of liposomes, the encapsulation efficiencies were >90%; the particle sizes were approximately 90 nm, and zeta potentials were slightly negative. The inhibitory effects were evaluated in the resistant breast cancer MCF-7/Adr cells. The results revealed that targeted sunitinib plus vinorelbine liposomes exhibited the strongest inhibitory effect to the resistant MCF-7/Adr cells among the varying formulations. Targeted coumarin liposomes were used as a fluorescent probe to evaluate the targeting effect to resistant breast cancer MCF-7/Adrcells. The results demonstrated that the targeted coumarin liposomes displayed the highest cellular uptake compared tonon-targeted formulations. In conclusion, the targeted sunitinib plus vinorelbine liposomes represented a novel type of nano-formulations, which could accumulate in the resistant breast cancer cells, thereby inhibiting proliferation of the resistant cancer cells. Accordingly, the targeted sunitinib plus vinorelbine liposomes may provide a new strategy for circumventing the drug resistance in the resistant breast cancer.

Key words: DSPE-PEG2000-pemetrexed, Sunitinib, Vinorelbine, Targeted liposomes, Resistant breast cancer

中图分类号:

R943

Supporting: Beijing Natural Science Foundation (Grant No. 7131009), the National Basic Research Program of China (Grant No. 973 program, 2013CB932501), the National Natural Science Foundation of China (Grant No. 81373343), and the Innovation Team of Ministry of Education (Grant No. BMU20110263).

石继凤, 居瑞军, 孙梦舸, 李秀英, 赵曜, 曾凡, 吕万良. 培美曲塞-磷脂偶联物修饰的靶向性舒尼替尼与长春瑞滨脂质体的研制及其在体外对耐药性乳腺癌的抑制效应[J]. 中国药学(英文版), 2014, 23(5): 287-294.

Jifeng Shi, Ruijun Ju, Mengge Sun, Xiuying Li, Yao Zhao, Fan Zeng, Wanliang Lu. Development of targeted sunitinib plus vinorelbine liposomes modified with DSPE-PEG2000-pemetrexed conjugate and the inhibitory effect toresistant breast cancer in vitro[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(5): 287-294.

参考文献

[1] Harris, A.L.; Hochhauser, D. Acta Oncol. 1992, 31, 205–213.

[2] Giovannini, M.; Aldrighetti, D.; Zucchinelli, P.; Belli, C.; Villa, E. Crit. Rev. Oncol. Hematol. 2010, 76, 13–35.

[3] Andrae, N.; Kirches, E.; Hartig, R.; Haase, D.; Keilhoff, G.; Kalinski, T.; Mawrin, C. Eur. J. Cancer. 2012, 48, 1831–1841.

[4] Kim, K.H.; Kim, H.Y.; Kim, H.R.; Sun, J.M.; Lim, H.Y.; Lee, H.J.; Lee, S.; Bae, W.K.; Rha, S.Y.; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee. Eur. J. Cancer. 2014, 50, 746–752.

[5] Ruka, W.; Rutkowski, P.; Szawlowski, A.; Nowecki, Z.; Debiec-Rychter, M.; Grzesiakowska, U.; Dziewirski, W.; Siedlecki, J.A.; Michej, W. Eur. J. Surg. Oncol. 2009, 35, 87–91.

[6] Curigliano, G.; Pivot, X.; Cortes, J.; Elias, A.; Cesari, R.; Khosravan, R.; Collier, M.; Huang, X.; Cataruozolo, P.E.; Kern, K.A.; Goldhirsch, A. Breast. 2013, 22, 650–656.

[7] Dai, C.L.; Liang, Y.J.; Wang, Y.S.; Tiwari, A.K.; Yan, Y.Y.; Wang, F.; Chen, Z.S.; Tong, X.Z.; Fu, L.W. Cancer Lett. 2009, 279, 74–83.

[8] Powles, T.; Sarwar, N.; Jones, R.; Wilson, P.; Boleti, E.; Protheroe, A.; Crabb, S.J.; Shamash, J.; Stockdale, A.; Rashid, S.; Nathan, P.; Chowdury, S. Eur. J. Cancer. 2012, 48, 3171–3176.

[9] Bhojani, N.; Jeldres, C.; Patard, J.J.; Perrotte, P.; Suardi, N.; Hutterer, G.; Patenaude, F.; Oudard, S.; Karakiewicz, P.I. Eur. Urol. 2008, 53, 917–930.

[10] Funakoshi, T.; Latif, A.; Galsky, M.D. Cancer Treat. Rev. 2013, 39, 818–830.

[11] Rebolj, K.; Bakrac, B.; Garvas, M.; Ota, K.; Sentjurc, M.; Potrich, C.; Coraiola, M.; Tomazzolli, R.; Dalla Serra, M.; Macek, P.; Sepcic, K. Biochim. Biophys. Acta. 2010, 1798, 891–902.

[12] Wang, M.; Thanou, M. Pharmacol. Res. 2010, 62, 90–99.

[13] Daidone, F.; Florio, R.; Rinaldo, S.; Contestabile, R.; di Salvo, M.L.; Cutruzzola, F.; Bossa, F.; Paiardini, A. Eur. J. Med. Chem. 2011, 46, 1616–1621.

[14] Rollins, K.D.; Lindley, C. Clin. Ther. 2005, 27, 1343–1382.

[15] Gonzalez-Cid, M.; Larripa, I.; Slavutsky, I. Toxicol. Lett. 1997, 93, 171–176.

[16] Fukuoka, K.; Arioka, H.; Iwamoto, Y.; Fukumoto, H.; Kurokawa, H.; Ishida, T.; Tomonari, A.; Suzuki, T.; Usuda, J.; Kanzawa, F.; Saijo, N.; Nishio, K. Lung Cancer. 2001, 34, 451–460.

[17] Zhou, J.; Zhao, W.Y.; Ma, X.; Ju, R.J.; Li, X.Y.; Li, N.; Sun, M.G.; Shi, J.F.; Zhang, C.X.; Lu, W.L. Biomaterials. 2013, 34, 3626–3638.

[18] Heidel, J.D.; Davis, M.E. Pharm. Res. 2011, 28, 187–199.

[19] Zhang, Z.; Huey Lee, S.; Feng, S.S. Biomaterials. 2007, 28, 1889–1899.

[20] Pan, J.; Feng, S.S. Biomaterials. 2009, 30, 1176–1183.

培美曲塞-磷脂偶联物修饰的靶向性舒尼替尼与长春瑞滨脂质体的研制及其在体外对耐药性乳腺癌的抑制效应

Development of targeted sunitinib plus vinorelbine liposomes modified with DSPE-PEG2000-pemetrexed conjugate and the inhibitory effect toresistant breast cancer in vitro

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	薛钧升, 王思媛, 郝方然, 田秀云, 苏红, 杨亮, 安启明, 郝纯毅, 周田彦. 多巴胺增强舒尼替尼治疗胰腺癌的药效[J]. 中国药学(英文版), 2020, 29(10): 689-700.
[2]	侯海涛, 宋子冰, 丁婕琴, 位灯国, 胡胜, 翟倩倩, 岳霞丽. 小檗碱通过靶向端粒G-四链体增强舒尼替尼的活性[J]. 中国药学(英文版), 2019, 28(5): 289-297.
[3]	谢红军, 刘磊, 曾凡, 沐黎敏, 赵曜, 阎妍, 胡英杰, 吴佳栓, 卜英子, 张婧莹, 吕万良. 抗耐药长春瑞滨脂质体及其抗耐药性乳腺癌的效应与机制研究[J]. 中国药学(英文版), 2016, 25(7): 489-501.
[4]	刘磊, 居瑞军, 谢红军, 曾凡, 张诚翔, 赵炜煜, 吕万良. 复方表阿霉素奎宁注射剂对耐药乳腺癌的治疗效应与机制研究[J]. 中国药学(英文版), 2015, 24(9): 563-571.
[5]	李静云, 李健, 王思媛, 袁茵, 苏青虹, 卢炜, 周田彦. 液相质谱串联法同时测定舒尼替尼及其活性代谢产物SU12662在BABL/c裸鼠血浆中的浓度及其药物动力学研究[J]. 中国药学(英文版), 2015, 24(4): 217-224.
[6]	杨勇杰, 李佳林, 王欢, 覃小雅, 卢晓静, 张兰馨, 张悦, 顾梦洁, 范田园. 液相色谱串联质谱法测定家兔血浆中舒尼替尼含量方法的建立与验证[J]. 中国药学(英文版), 2015, 24(11): 721-725.
[7]	赵子明, 李佳林, 杨勇杰, 崔代超, 卢晓静, 范田园. 载舒尼替尼栓塞微球的制备及体外性质研究[J]. 中国药学(英文版), 2014, 23(8): 558-564.